CFTR and cystic fibrosis: Of greater importance will be the impact of so called ‘triple therapy’ (elexacaftor/ivacaftor/tezacaftor)—this highly effective CFTR modulator therapy produced very impressive results in clinical trials and will be potentially prescribed to up to 90% of the CF population19,20.